NBD AI Bulletin -- Shijiazhuang Yiling Pharmaceutical Co., Ltd. (the Company, SZ 002603, closing price: 27.67 yuan) released its earnings report on October 26. For the first three quarters of 2020, revenue comes in at about 6.447 billion yuan, an increase of 48.31% year on year; Net profit stands at about 1.016 billion yuan, an increase of 76.74% year on year; Basic earnings per share is 0.850 yuan, an increase of 77.08% year on year.
According to the semi-annual report of 2020, Shijiazhuang Yiling Pharmaceutical Co., Ltd. mainly engages in pharmaceutical manufacturing, accounting for 99.61% of its revenue.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s chairman is Wu Yiling, male, 71 years old, Chinese national, no permanent residence abroad, professor of Hebei Medical University, doctoral advisor, member of Chinese Academy of Engineering, traditional Chinese medicine cardiovascular expert. Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s general manager is Wu Xiangjun, male, 45 years old, Chinese national, no permanent residence abroad, master's degree in traditional Chinese medicine, MBA from University of Greenwich, UK.
Tips on "Stock Trends":
1. The number of shares held by northbound investors increased by 6.6709 million in the past 30 days, representing 0.68% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
(By Tan Yuhan)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.